lapatinib has been researched along with Barrett Esophagus in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Canto, M; Ding, P; Dunbar, KB; Eshleman, JR; Feldmann, G; Goff, D; Haffner, MC; Heckrodt, TJ; Hector, A; Holland, SJ; Hong, SM; Karikari, C; Maitra, A; Marimuthu, A; Meeker, AK; Montgomery, EA; Nelkin, BD; Pandey, A; Riggins, GJ; Roa, JC; Singh, R; Wang, JS; Yu, J; Zhang, J | 1 |
1 other study(ies) available for lapatinib and Barrett Esophagus
| Article | Year |
|---|---|
The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Axl Receptor Tyrosine Kinase; Barrett Esophagus; Benzocycloheptenes; Cell Movement; Esophageal Neoplasms; Female; Humans; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Lapatinib; Lymphatic Metastasis; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; ral GTP-Binding Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Survival Rate; Triazoles | 2010 |